Pulmonary Manifestations of Polymyositis/Dermatomyositis

Robert W. Hallowell, MD1 Dana P. Ascherman, MD2 Sonye K. Danoff, MD, PhD1,3

1Division of Pulmonary and Critical Medicine, John Hopkins School of Medicine, Baltimore, Maryland
2Division of Rheumatology, University of Miami Health System, Miami, Florida
3Johns Hopkins Myositis Center, John Hopkins School of Medicine, Baltimore, Maryland


Address for correspondence Sonye K. Danoff, MD, PhD, Division of Pulmonary and Critical Medicine, Johns Hopkins School of Medicine, 1830 E. Monument Street, 5th Floor, Baltimore, MD 21205 (e-mail: sdanoff@jhmi.edu).

The idiopathic inflammatory myopathies

The idiopathic inflammatory myopathies (IIMs) are a group of connective tissue diseases marked by varying degrees of muscle inflammation and clinical involvement of multiple organs, most notably, the lung. Pulmonary manifestations consist primarily of interstitial lung disease (ILD), which is associated with significant morbidity and mortality in myositis patients. Several myositis-specific antibodies have been discovered, as well as antibodies targeting various aminoacyl-tRNA synthetase enzymes. These antibodies are associated with various clinical features and a risk for developing ILD, and their presence carries a prognostic value in myositis patients. Steroids remain the first-line treatment for myositis-associated ILD and the antisynthetase syndrome, though other traditional immunosuppressants have demonstrated efficacy in numerous studies. While a majority of patients experience either stabilization or improvement in lung imaging and function, fatal progression is still reported in a significant number of cases. Further research is needed to develop more effective and targeted therapies.

The Antisynthetase Syndrome

In recent years, several myositis-specific autoantibodies (MSAs) have been discovered: antisignal recognition particle (anti-SRP) antibodies, anti-Mi-2 antibodies, anti-PM/Scl antibodies, anti-aminoacyl-tRNA synthetase (ARS) antibodies, anticlinically ADM-140-kDa polypeptide antibodies (anti-CADM-140 antibodies or melanoma differentiation-associated gene 5 [MDA-5]), and anti-155/140-kDa polypeptide antibodies (anti-155/140 antibodies)16–19 (–Table 1). Among these MSAs, ARS antibodies target the cytoplasmic ARS enzymes that are responsible for loading each tRNA with a specific amino acid before it is incorporated into a growing peptide at the level of the ribosome.20 There are 20 different
amino acids, each of which has a cognate tRNA synthetase. To date, antibodies specific for eight of these synthetases have been detected and implicated in connective tissue disease: antihistidyl- (anti-Jo-1), antithreonyl- (anti-PL-7), antialanyl- (anti-PL-12), antiisoleucyl- (anti-OJ), antiisopropyl- (anti-KS), antiisophenylalanyl- (anti-Zo), and antiisoyosyl-tRNA- (anti-YRS) tRNA synthetase (Table 2). The presence of an ARS antibody in conjunction with inflammatory myositis or ILD has collectively come to be known as the antisynthetase syndrome, with additional clinical features that can include nonerosive arthritis, fever, mechanic’s hands (Fig. 1), and Raynaud phenomenon. While the concomitant presence of other autoimmune antibodies is not uncommon, overlap between the ARS antibodies themselves is rare. Specific ARS antibodies are associated with different subphenotypes characterized by a varying prevalence of myositis, ILD, and other clinical manifestations of connective tissue disease. In general, the presence of any ARS antibody confers a substantially higher risk for developing ILD, with multiple studies demonstrating a prevalence of 67 to 100% depending on the specific antibody identified.

<table>
<thead>
<tr>
<th>Table 1 Myositis-specific antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Myositis-associated antibodies</strong></td>
</tr>
<tr>
<td>Anti-Ro52</td>
</tr>
<tr>
<td>Anti-MDA-5</td>
</tr>
<tr>
<td>Anti-155/140</td>
</tr>
<tr>
<td>Anti-SRP</td>
</tr>
<tr>
<td>Anti-Mi-2</td>
</tr>
</tbody>
</table>

| Abbreviations: CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; MDA-5, melanoma differentiation–associated gene 5; SRP, signal recognition particle. |

<table>
<thead>
<tr>
<th>Table 2 Antisynthetase antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antisynthetase antibodies (ARS)</strong></td>
</tr>
<tr>
<td>Anti-Jo-1</td>
</tr>
<tr>
<td>Anti-EJ</td>
</tr>
<tr>
<td>Anti-PL-7</td>
</tr>
<tr>
<td>Anti-OJ</td>
</tr>
<tr>
<td>Anti-PL-12</td>
</tr>
<tr>
<td>Anti-KS</td>
</tr>
<tr>
<td>Anti-Zo</td>
</tr>
<tr>
<td>Anti-YRS</td>
</tr>
</tbody>
</table>

| Abbreviations: ARS, antiamoacyl-tRNA synthetase; CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease. |
Anti-MDA-5 (Anti-CADM-140) Antibodies

In addition to the ARS antibodies, a 140-kDa cytoplasmic protein was identified as being highly associated with clinically ADM (C-ADM) and subsequently named anti-CADM-140. In 2009, Sato et al discovered that anti-CADM-140 reacts with an RNA helicase encoded by MDA-5, and the antibody was subsequently renamed as anti-MDA-5. Despite its original name, anti-MDA-5 antibodies can be associated with clinically active myositis. Anti-MDA-5 often produces a phenotype that mimics the antisynthetase syndrome; however, it is also associated with characteristic skin findings including tender palmar papules and deep ulcerations with punched out borders and necrosis (Fig. 2). Furthermore, anti-MDA-5 antibodies are rarely found in other connective tissue diseases such as rheumatoid arthritis and systemic lupus erythematosus. Anti-MDA-5 antibodies confer a high risk for the development of ILD and have been associated with rapidly progressive and acute/subacute interstitial pneumonia in several cohorts. Furthermore, the presence of anti-MDA-5 antibodies represents an individual risk factor for death from ILD in DM patients. In one study, anti-MDA-5 antibody levels correlated with the severity of high-resolution computed tomography (CT) scores in patients with ILD. In addition, patients with anti-MDA-5 levels greater than 500 units/mL were found to have more treatment-resistant lung disease and skin ulcerations, with a higher rate of respiratory failure and death compared with patients with levels less than 500 units/mL. Overall, then, anti-MDA-5 titers seem to correlate with treatment response and survival in patients with ILD.

The pathophysiology linking anti-MDA-5 titers with the severity of ILD is poorly understood, though some have suggested a relationship to underlying vascular pathology. MDA-5 is an RNA helicase that recognizes the double stranded RNA of picornaviruses to induce the production of type-1 interferons and tumor necrosis factor as part of the innate antiviral immune response. One hypothesis postulates that anti-MDA-5 antibodies are somehow generated during a viral infection, perhaps through an aberrant, overly exuberant immune response.

Anti-155/140 Antibodies

The third group of myositis-specific antibodies includes those targeting 155/140-kDa polypeptides (anti-155/140 antibodies) corresponding to TIF1 transcription factors. Anti-155/140 antibodies are found in 13 to 16% of DM/PM patients and are highly associated with the presence of malignancy in adults. However, in contrast to ARS and anti-MDA-5 antibodies, anti-155/140 antibodies are associated with a lower risk of ILD.

Anti-PM/Scl and Anti-Ro Antibodies

Other antibodies associated with DM/PM and ILD include anti-PM/Scl and anti-Ro52. When present in myositis patients, anti-PM/Scl antibodies are associated with clinical features resembling those of the antisynthetase syndrome. ILD is present with a high frequency in anti-PM/Scl positive patients, though pulmonary disease tends to occur after the appearance of other connective tissue disease manifestations.

Anti-Ro-52 is an antibody found in numerous connective tissue diseases—including systemic lupus erythematosus, mixed connective tissue disease, and DM/PM—and its presence is associated with an increased risk of ILD. Anti-Ro-52 is commonly found in patients with the antisynthetase syndrome and has been reported in 19% of patients with ARS antibodies as well as patients with other myositis-specific antibodies. Overall, 20% of patients with DM/PM express anti-Ro-52 antibodies, though the frequency of anti-Ro-52 is higher among those with ILD; in fact, one cohort reported that 90% of DM/PM patients with ILD were reactive to anti-Ro-52. Furthermore, in a cohort of anti-Jo1 positive patients, the presence of anti-Ro52 antibodies was associated with a high frequency of ILD.
with higher total high-resolution computed tomography (HRCT) scores as well as worse myositis, joint involvement, and survival. Collectively, these observations suggest that the coexistence of anti-Ro52 and anti-Jo-1 antibodies may be predictive of a more aggressive disease course.

**Anti-SRP and Anti-Mi-2 Antibodies**

Anti-SRP antibodies recognize the SRP, a cytoplasmic protein that regulates the movement of proteins through the endoplasmic reticulum. These autoantibodies are found in roughly 5% of IIM patients and are associated with severe myositis marked by profound weakness and highly elevated muscle enzymes. Unlike antisynthetase antibodies, anti-SRP antibodies do not confer an increased risk of developing ILD, and some authors even contend that the risk of pulmonary disease is actually decreased in anti-SRP-positive patients when compared with myositis controls.

Mi-2 is a nuclear helicase protein comprising the nucleosome-remodeling deacetylase complex involved in DNA transcription. Unlike anti-SRP antibodies, anti-Mi-2 antibodies are more common in patients with DM than PM and are often associated with less severe muscle involvement. However, like anti-SRP antibodies, they are not associated with an increased risk of myositis-associated ILD.

**Genetic Factors**

There is growing evidence that genetic factors may influence the development of ILD in patients with DM/PM and the antisynthetase syndrome. In one cohort of British patients with DM/PM, ILD was more common in patients of black ethnicity. In addition, numerous reports have indicated a higher prevalence of rapidly progressive ILD in cohorts from Eastern Asia with ADM and anti-MDA-5 antibodies, with many cases that have proven refractory to immunosuppressive therapy. However, in an American cohort of anti-MDA-5 positive patients, most cases of ILD were responsive to immunosuppressive therapy. While all of these studies are limited by small sample size, they may indicate that various autoimmune antibodies can be associated with different phenotypes in different ethnic backgrounds.

Genetic studies have identified an association between the DRB1*03-DQA1*05-DQB1*02 haplotype and the presence of both ARS antibodies and ILD. Conversely, HLA-DRB1*07-DQA1*02-DQB1*02 is associated with a decreased risk of ILD. Furthermore, while HLA-DRB1*0301 is relatively common in Caucasians with ARS antibody-positive DM/PM, the frequency of HLA-DRB1*0301 is low in the Japanese population. However, HLA-DRB1*0405, found in 20% of the Japanese population, is highly associated with anti-MDA-5 antibody-positive DM and associated ILD.

**CT Imaging in DM/PM and the Antisynthetase Syndrome**

The CT findings of patients with DM/PM and the antisynthetase syndrome can be highly variable depending on the severity and acuity of their pulmonary symptoms. While patients presenting with acute ILD tend to have ground glass opacities and consolidations, patients presenting with a more chronic course of ILD have more evidence of reticulation and honeycombing. In both groups, parenchymal abnormalities are predominantly in a basilar and subpleural distribution. Interestingly, ground glass and reticular opacities can be associated with fatal cases of ILD, while a consolidative pattern is associated with nonfatal disease. Other patterns described with less frequency in DM/PM and the antisynthetase syndrome include traction bronchiectasis and subpleural condensations (Fig. 3).

**Pulmonary Function Testing**

Patients with ILD associated with myositis and the antisynthetase syndrome tend to have a restrictive pattern on pulmonary function tests (PFTs) with generally mild reductions in forced vital capacity (FVC, 70–79% predicted) and mild to moderate reductions in the diffusing capacity for carbon monoxide (DLCO); however, a wide range has been reported, and there have been no definitive studies to suggest that specific myositis-associated antibodies are linked with more severe PFT abnormalities. Total lung capacity (TLC) and FVC have been used to monitor disease progress as well as therapeutic response, and there is evidence that a lower FVC and DLCO at the time of ILD diagnosis predict a worse prognosis. However, PFTs in patients with myositis must be interpreted with caution, since respiratory muscle weakness alone can result in restrictive physiology, even in the absence of ILD. Conversely, PFTs may appear to improve despite persistent or worsening pulmonary disease as muscle weakness responds to corticosteroid or immunomodulatory therapy.

**Pneumomediastinum**

Spontaneous pneumomediastinum is a rare complication of DM associated with significant morbidity and mortality. One review reported that one-quarter of patients died in the first month, with a cumulative survival rate of only 64% at 1 year and 55% at 2 years. Although pneumomediastinum in patients with PM has been reported, the vast majority of cases have occurred in patients with DM. The pathogenesis of pneumomediastinum in patients with myositis is poorly understood, though it is speculated to result from the rupture of subpleural blebs that occur with ILD, leading to dissection of air around perivascular sheaths and into the mediastinum. However, there have been reports of pneumomediastinum occurring in DM patients without known ILD, and some have speculated that vasculopathy may also be playing a role by disrupting the bronchial mucosal barrier and causing subpleural infarctions.

**Pathology**

Open lung biopsy is often not performed in patients with DM/PM or the antisynthetase syndrome, partly because the
results of such a biopsy may not influence the choice of immunosuppressant therapy. However, multiple studies have reported limited pathology with mixed results. Marie et al studied a cohort of 107 patients with DM/PM and found nonspecific interstitial pneumonia (NSIP) in 61%, cryptogenic organizing pneumonia (COP) in 22%, and usual interstitial pneumonia (UIP) in 17% of the 41 biopsy samples available. The prevalence of various MSAs was not evaluated in this study, though there is some evidence that various ARS antibodies may not necessarily be associated with any particular histologic pattern of ILD. For instance, Koreeda et al reported biopsies on four patients positive for different ARS antibodies, each of which demonstrated an NSIP pattern with lymphocytes and plasma cells infiltrating the interstitium. Furthermore, biopsies from three patients with idiopathic interstitial pneumonia in the setting of anti-OJ antibody reactivity demonstrated three different histologic patterns: NSIP, UIP, and COP. In another study, three out of five biopsies in patients with anti-PL-7 antibodies demonstrated a UIP pattern, while NSIP was the most common pattern in a group of 22 patients with anti-Jo-1 antibodies. Further demonstrating the high degree of variability in these studies, Richards et al showed that UIP was three times more common than NSIP in another cohort of anti-Jo-1 positive patients. Moreover, an additional study reported that four out of five patients with myositis who developed respiratory failure were found to have diffuse alveolar damage on biopsy with a mortality rate of 100%. Therefore, while it is possible that associations exist between specific antibodies and certain histologic patterns, no studies to date have been large enough to conclusively determine the nature of such associations.

**Treatment**

Steroids remain the first-line therapy for ILD in patients with DM/PM or the antisynthetase syndrome. Oral regimens include 1 mg/kg of prednisone daily, often following an initial pulse of intravenous methylprednisolone at a dose of 1,000 mg daily for 3 days in severe cases. While some patients with ILD and myositis will have an adequate response to corticosteroid monotherapy, the need for additional immunosuppression, especially in the case of rapidly progressing acute/subacute ILD, is common. Interestingly, the presence of ARS antibodies may predict a better ILD response to steroids in myositis patients, though additional factors influencing the outcome of steroid treatment include the relative timing of ILD and myositis onset.

Azathioprine has been used in patients with anti-Jo-1 ILD either as maintenance therapy following cyclophosphamide or as a steroid-sparing agent in patients receiving concomitant prednisone, with roughly 58% of patients demonstrating either resolution or significant improvement in pulmonary status.

The safety of mycophenolate mofetil for the treatment of numerous connective tissue diseases is well established, though its efficacy for ILD remains in question. There have been reports of DM-ILD patients with either significant improvement or complete resolution of their ILD following treatment with mycophenolate mofetil, including a case series of four patients who had improvement with mycophenolate mofetil after treatment with steroids and azathioprine proved to be ineffective.

**Fig. 3** CT findings in patients with myositis-associated antibodies. (A) Biopsy-proven AIP in a patient with anti-EJ antibodies. (B) Biopsy-proven NSIP in a patient with anti-Jo-1 antibodies. (C) Biopsy-proven UIP in a patient with anti-PL-12 antibodies. (D) ILD in a patient with anti-MDA-5 antibodies. (E) Spontaneous pneumomediastinum in a patient with anti MDA-5 antibodies. AIP, acute interstitial pneumonitis; CT, computed tomography; ILD, interstitial lung disease; MDA-5, melanoma differentiation–associated gene 5; UIP, usual interstitial pneumonia.
Cyclophosphamide, a nitrogen mustard alkylating agent, has also been used with some efficacy in treating myositis-related ILD.\textsuperscript{15,80} One study by Yamasaki et al used an intravenous dose of 300 to 800 mg/m\textsuperscript{2} at least six times every 4 weeks to treat refractory ILD and demonstrated both functional and radiographic improvement in the majority of patients.\textsuperscript{83} Another study reported either resolution or a significant improvement in pulmonary status in 72\% of anti-Jo-1 ILD patients treated with cyclophosphamide based on symptoms, PFTs, and HRCT imaging.\textsuperscript{15} However, Ingegnoli et al observed improvement in only four of eight anti-Jo-1 PM ILD patients treated with a cyclophosphamide pulse plus steroids.\textsuperscript{84}

Several studies have also highlighted a possible benefit of using cyclosporine A (CsA) to treat steroid-resistant ILD.\textsuperscript{78,85} Takada et al found that after 4 weeks of treatment, essentially all DM and PM patients diagnosed as having chronic ILD had at least some response to a combination of CsA and corticosteroids. Unfortunately, their results were less promising in those patients presenting with acute ILD; after 4 weeks of combination treatment, fewer than 50\% of these patients had a partial response, and there were two reported deaths. Moreover, remission by the last clinical evaluation was only observed in roughly half the acute ILD patients, with an additional three deaths recorded over time. Interestingly, however, this study also seemed to suggest that patients who received a combination of CsA and steroids up front had better outcomes than those who initially received only steroids.\textsuperscript{85} In contrast, Ingegnoli et al reported that five out of seven patients with anti-Jo-1-positive PM who were treated with CsA manifested CT evidence of worsening ILD, though the acuity of their ILD was not reported.\textsuperscript{84}

There is evidence that the related calcineurin inhibitor tacrolimus may be superior to CsA, as several patients in the Takada study who had persistently active ILD despite prednisolone and CsA therapy demonstrated a prompt response to tacrolimus.\textsuperscript{85} Other reports have also demonstrated the efficacy of tacrolimus in the treatment of anti-Jo-1-associated ILD.\textsuperscript{86}

### Table 3: Studies reporting various treatment modalities for DM/PM-associated ILD

<table>
<thead>
<tr>
<th>Study lead author, year</th>
<th>Total no. of ILD patients</th>
<th>CS alone</th>
<th>CYC</th>
<th>AZA</th>
<th>MMF</th>
<th>CsA</th>
<th>Tacro</th>
<th>RTX</th>
<th>MTX</th>
<th>IVIG</th>
<th>Pulmonary improvement, stabilization (%)</th>
<th>Mortality, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kono et al, 2000\textsuperscript{71}</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NR</td>
<td>1 (25)</td>
</tr>
<tr>
<td>Lee et al, 2002\textsuperscript{70}</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NR</td>
<td>5 (100)</td>
</tr>
<tr>
<td>Fujisawa et al, 2005\textsuperscript{85}</td>
<td>28</td>
<td>7</td>
<td>8</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NR</td>
<td>8 (29)</td>
</tr>
<tr>
<td>Kameda et al, 2005\textsuperscript{80}</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NR</td>
<td>5 (50)</td>
</tr>
<tr>
<td>Takada et al, 2005\textsuperscript{85}</td>
<td>32</td>
<td>8</td>
<td>32</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>19 (59)</td>
<td>10 (31)</td>
</tr>
<tr>
<td>Wilkes et al, 2005\textsuperscript{86}</td>
<td>13</td>
<td>2</td>
<td>5</td>
<td>13</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Ye et al, 2007\textsuperscript{72}</td>
<td>21</td>
<td>5</td>
<td>8</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NR</td>
<td>12 (57)</td>
</tr>
<tr>
<td>Yamasaki et al, 2007\textsuperscript{84}</td>
<td>17</td>
<td>5</td>
<td>17</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>17 (17)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Ideura et al, 2007\textsuperscript{84}</td>
<td>18</td>
<td>3</td>
<td>2</td>
<td>13</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13 (72)</td>
<td>5 (28)</td>
</tr>
<tr>
<td>Fathi et al, 2008\textsuperscript{8}</td>
<td>23</td>
<td>11</td>
<td>11</td>
<td>4</td>
<td>10</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13 (72)</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Hayashi et al, 2008\textsuperscript{5}</td>
<td>33</td>
<td>25</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NR</td>
<td>9 (27)</td>
</tr>
<tr>
<td>Suzuki et al, 2009\textsuperscript{89}</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (40)</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Sem et al, 2009\textsuperscript{87}</td>
<td>11</td>
<td>8</td>
<td>7</td>
<td>4</td>
<td>11</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7 (64)</td>
<td>1 (9)</td>
</tr>
<tr>
<td>Kalluri et al, 2009\textsuperscript{81}</td>
<td>31</td>
<td>1</td>
<td>9</td>
<td>11</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Mukae, 2009\textsuperscript{84}</td>
<td>27</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NR</td>
<td>6 (22)</td>
</tr>
<tr>
<td>Hervier et al, 2010\textsuperscript{85}</td>
<td>17</td>
<td>6</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6/10 (60)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Koreeda et al, 2010\textsuperscript{14}</td>
<td>14</td>
<td>6</td>
<td>1</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>12 (86)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Ji et al, 2010\textsuperscript{71}</td>
<td>69</td>
<td>23</td>
<td>16</td>
<td>7</td>
<td>6</td>
<td>2</td>
<td>36</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>24 (34)</td>
<td></td>
</tr>
<tr>
<td>Morganroth et al, 2010\textsuperscript{82}</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Lega et al, 2010\textsuperscript{80}</td>
<td>22</td>
<td>9</td>
<td>4</td>
<td>5</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>14 (64)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Marie et al, 2011\textsuperscript{87}</td>
<td>107</td>
<td>56</td>
<td>25</td>
<td>38</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>90 (84)</td>
<td>7 (7.5)</td>
</tr>
<tr>
<td>Bakewell and Raghu, 2011\textsuperscript{90}</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (100)</td>
<td>1 (100)</td>
</tr>
<tr>
<td>Muro et al, 2012\textsuperscript{86}</td>
<td>10</td>
<td>5</td>
<td>3</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Kunimas et al, 2012\textsuperscript{24}</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (100)</td>
<td>2 (100)</td>
</tr>
<tr>
<td>Ingegnoli et al, 2012\textsuperscript{84}</td>
<td>15</td>
<td>3</td>
<td>8</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4 (27)</td>
<td>NR</td>
</tr>
<tr>
<td>Cao et al, 2012\textsuperscript{88}</td>
<td>15</td>
<td>1</td>
<td>13</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (13/18)</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Marie et al, 2013\textsuperscript{16}</td>
<td>66</td>
<td>31</td>
<td>17</td>
<td>27</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>55 (83)</td>
<td>6 (9)</td>
</tr>
</tbody>
</table>

Abbreviations: IVIG, intravenous immunoglobulin; NR, not reported.
Rituximab, a monoclonal antibody directed against the B cell surface marker CD20, has demonstrated some efficacy in treating ILD in a group of anti-Jo-1–positive patients after 6 months in combination with prednisone; however, the true utility of rituximab was hard to evaluate since the majority of patients had received various other immunosuppressant agents both before and after rituximab was used.87–89

Based on evidence implicating a possible role for TNF−α in the immunopathology of IIM, investigators have also used the TNF inhibitor adalimumab to successfully treat Jo-1 antibody–positive ILD.85 In addition, there have been reports of DM/PM–associated ILD that is refractory to high-dose steroids and CsA treated successfully with intravenous immunoglobulin,85,86 though significant data on the utility of such treatment are still lacking.

**Clinical Course**

Because myositis–associated ILD is a rare condition, most outcome analyses are reflective of case series or small, poorly controlled studies. Nevertheless, the available evidence suggests that outcomes in DM/PM and the antisynthetase syndrome are largely driven by the ILD phenotype, and to some extent, the presence of specific autoantibodies. Multiple reports have shown that patients with acute/subacute ILD in C-ADM often do not respond to therapy with corticosteroids and other immunosuppressive agents.4,10,44,91 By contrast, patients with radiologic or histologic evidence of an NSIP or COP pattern tend to be more responsive to steroid therapy.15,67 Furthermore, the presence of ARS antibodies in patients with ILD may predict greater steroid responsiveness, though with an increased risk of recurrence.78

Fathi et al followed patients with DM/PM ILD for 35 months after the initiation of treatment with corticosteroids plus another immunosuppressive agent and found that TLC improved in 38% of patients and deteriorated in 28%, with the remaining patients being labeled as stable. Interestingly, there were also several patients in whom PFTs normalized despite persistent radiographic abnormalities.8 In a similar DM/PM population, Won Huh et al demonstrated increased PVC and DLCO 6 months following treatment, an improvement that was sustained for up to 3 years.4 Likewise, Marie et al evaluated 107 patients with DM/PM ILD and found resolution in 32.7% and improvement in 51.4% with only 15.9% of patients deteriorating.67 Kureeda et al reported improvement in 12 out of 14 patients with ARS antibodies treated with either steroids or CsA, though there was one case of progressive worsening and death despite an initial improvement at 6 months.14

Treatment results in ARS antibody–positive patients may be more favorable, with evidence that an NSIP or COP pattern on HRCT confers a greater probability of steroid responsiveness in anti-Jo-1 patients with ILD.15 In a cohort of 28 anti-Jo-1 patients with ILD, for example, there was resolution in 25%, clinical improvement or stability in 54%, and worsening in 21%.32 Other studies of anti-Jo-1 ILD patients have shown similar results, with remission noted in 29% of patients and improvement or stabilization in upward of two-thirds of patients, the majority of which were treated with either corticosteroids or a combination of corticosteroids plus immunosuppressive drugs.26,92 Furthermore, Marie et al demonstrated resolution of rapidly progressive, acute onset ILD in 8 of 12 anti-Jo-1 patients treated with steroids and either CsA, azathioprine, or mycophenolate.15 Conversely, Ingegnoli et al showed less promising outcomes in a group of 15 patients with anti-Jo-1 PM; 60% had a worsening of their ILD 12 months after diagnosis.84 Finally, although a group of patients with anti-PL-7 antibodies showed some improvement with treatment in 64.3% of cases, no patients experienced frank resolution—a pattern also seen in some patients with nonspecified DM/PM or anti-Jo-1–associated ILD.34

Overall, the biggest factor determining survival rates in patients with DM/PM and the antisynthetase syndrome is the presence of ILD. Marie et al demonstrated an overall mortality rate of 7.5% for myositis–associated ILD, with 87.5% of deaths attributable to the patients’ lung disease.67 Ji et al showed a DM/PM mortality rate of 34.8% in patients with ILD versus 8.6% in patients without ILD.7 Similarly, the mortality rate among DM/PM patients in a Chinese cohort was 43.9% in patients with ILD versus 24.5% in patients without ILD.6 Finally, Hayashi et al demonstrated a mortality rate of 12% in PM ILD patients versus 44% in DM ILD patients, with most of the deaths in the DM group attributable to rapidly progressive lung disease.3 Indeed, acute ILD seems to portend a much worse prognosis than its chronic counterpart,3,7 with early (2 months) mortality rates as high as 72.7% in some cohorts of DM/PM ILD patients.4

**Conclusions**

The IIMs are a group of connective tissue diseases that include PM, DM, and ADM. Over the years, various MSAs have been identified, and their presence is associated with varying clinical phenotypes and propensities for the development of ILD. ILD in patients with DM/PM is associated with significant morbidity and mortality, and treatment typically consists of high-dose corticosteroids, often in conjunction with additional immunosuppressive agents. Although a majority of patients with ILD demonstrate either stability or improvement following treatment, there remains a subset of patients with fatal progression of their pulmonary disease. Further research in this field will require more detailed molecular profiling, more rigorous standardization of clinical data collection, improved consensus regarding outcome measures, and more balanced data sharing between institutions. The result will hopefully be a better understanding of the mechanisms underlying ILD, leading to more effective and targeted therapies.

**References**

Pulmonary Manifestations of Polymyositis/Dermatomyositis

Hallowell et al.


40 Kang EH, Nakashima R, Mimori T, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive
interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010;11:223


Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 2010;138(6):1464–1474


